Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H3L1
- Development stage
- Preclinical
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
H3L1 is a monoclonal antibody targeting coagulation factor IXa (FIXa) under development by Shanghai Jiao Tong University School of Medicine for the treatment of thrombosis. It binds with high affinity to FIXa, competing with its cofactor, coagulation factor VIIIa (FVIIIa), to block their interaction and inhibit thrombin generation. In preclinical models of carotid artery and venous thrombosis, H3L1 demonstrated significant antithrombotic efficacy with a low risk of bleeding, and its effects were shown to be reversible by FVIIIa.
02
Targets
F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on H3L1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H3L1.